Wigs are considered a temporary solution for hairloss, with concerns about cost, maintenance, and social stigma. Many prefer treatments like finasteride, minoxidil, or hair transplants for more permanent results.
Researching the cause of hairloss and treating it by preventing DHT in the scalp with medication such as finasteride or dutasteride, estrogen, minoxidil, dermarolling, and possible topical antiandrogens.
A regimen for hairloss, which includes using Nizoral shampoo twice daily, Minoxidil foam from the can, 5mg of Propecia crushed and snorted on weekends, and dermastamping directly to the head of the penis. Replies discuss potential sides and other treatments, as well as the idea that confidence is more attractive than hair.
The conversation discusses potential hairloss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.
There is no imminent cure for hairloss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hairloss and stimulating growth, with hopes for better options in the future.
Developing new hairloss treatments is challenging due to the complexity and cost of trials, and a permanent cure is unlikely soon. Current treatments like Minoxidil and finasteride are used continuously because hairloss is progressive, and future possibilities include gene editing and hair cloning.
PP405 is a new topical treatment for hairloss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
A potential treatment for hairloss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.
PP405 is not a cure for hairloss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
PP405 is the most promising future treatment for hairloss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hairloss and minoxidil to stimulate growth.
There is no permanent cure for hairloss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.
The conversation is about the effectiveness of hairloss treatments like finasteride, dutasteride, and minoxidil. Users agree these treatments help maintain hair but don't guarantee miraculous regrowth, emphasizing early intervention for best results.
The conversation is about future hairloss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
The user is seeking natural hairloss treatments, avoiding finasteride due to side effects. They mention considering a $1,000 LLT helmet, Nutrafol supplements, and various unproven remedies.
PP405 is a promising hair growth stimulant but not a cure for advanced hairloss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.
The conversation humorously suggests that the hairloss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.
UCLA's PP405 shows promise in reactivating dormant hair follicles for hairloss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
The conversation discusses potential hairloss treatments, including methylating estrogen, losing body fat, and supplementing with vitamins A, K2, and D. It also mentions reducing exposure to environmental estrogenics, with skepticism about genetic factors being the primary cause of baldness.
PP405 is considered a promising potential cure for hairloss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
HMI 115 is being discussed as a potential hairloss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
Clascoterone is being discussed as a promising new hairloss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.
Topical finasteride that doesn't penetrate the skin could potentially treat hairloss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.
The post and conversation discuss Verteporfin's potential as a hairloss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.
The conversation humorously discusses using anal administration of Dutasteride as a novel method for treating hairloss, suggesting it could target DHT production more effectively. It includes satirical comments about the method's potential effects and absurd outcomes.
The post discusses a new hairloss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.